Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 52.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 21,100 shares of the biopharmaceutical company’s stock after purchasing an additional 7,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Celldex Therapeutics were worth $533,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CLDX. Wellington Management Group LLP raised its holdings in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company’s stock worth $314,190,000 after purchasing an additional 1,167,659 shares during the period. Jennison Associates LLC raised its holdings in shares of Celldex Therapeutics by 32.0% during the third quarter. Jennison Associates LLC now owns 1,324,410 shares of the biopharmaceutical company’s stock valued at $45,017,000 after acquiring an additional 321,325 shares during the last quarter. Emerald Advisers LLC raised its holdings in shares of Celldex Therapeutics by 129.9% during the third quarter. Emerald Advisers LLC now owns 456,202 shares of the biopharmaceutical company’s stock valued at $15,506,000 after acquiring an additional 257,773 shares during the last quarter. Fisher Asset Management LLC raised its holdings in shares of Celldex Therapeutics by 210.6% during the third quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company’s stock valued at $12,724,000 after acquiring an additional 253,808 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new position in shares of Celldex Therapeutics during the third quarter valued at approximately $6,102,000.

Celldex Therapeutics Price Performance

CLDX stock opened at $20.57 on Friday. The firm has a market capitalization of $1.36 billion, a PE ratio of -8.00 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1 year low of $19.83 and a 1 year high of $53.18. The business has a 50 day simple moving average of $23.86 and a 200-day simple moving average of $28.92.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Analyst Ratings Changes

CLDX has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a report on Friday. Finally, UBS Group started coverage on Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $56.50.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.